Chief Strategy Officer / CXO / CEO
Board-ready AI summaries, top opportunity rankings, and portfolio risk alerts, with confidence the data is live and complete.
Atlas · Molecule Intelligence Platform
Every molecule. Every signal. One platform.
Atlas aggregates 20 real-world data sources, clinical trials, regulatory filings, safety alerts, literature and market news, into a single platform that scores, ranks and summarises your molecule pipeline automatically.
atlas · molecule
C21H30O2
Trials12 active
Patents31 cited
Publications240
Landscape4 rivals
- 17,000+
- molecules scored across 10 dimensions
- 20
- live real-world data sources
- 14
- integrated intelligence capabilities
- 4
- trial registries unified in one view
- 3
- literature databases cross-searched
- 1
- platform replacing weeks with hours
01 The problem
Why portfolio decisions are broken
Pharma companies, CDMOs and biotech teams spend weeks assembling intelligence that should take hours. Trials, regulatory data, safety systems, literature and market news all live in separate silos, forcing analysts to stitch together spreadsheets and PDFs before a single strategic discussion can happen.
Data fragmentation
Portfolio decisions depend on data from dozens of disconnected sources. Today that means manual assembly across spreadsheets and emails.
No molecule-level 360° view
There's no single place to see where a molecule stands across every dimension at once: approval status, active trials, adverse-event signals, competition, patent expiry, and recent news.
Review cycles take weeks
Scoring a pipeline of thousands of molecules takes expert analyst time over multiple weeks per cycle, making strategic reviews slow, expensive, and inconsistent.
Intelligence isn't automated
Insights are locked inside expert heads and static reports. Nothing continuously pulls from live sources and surfaces signals before they become urgent.
Enterprise tools are out of reach
Smaller pharma teams and CDMOs can't afford SAP- or Oracle-scale platforms, yet they need the same quality of intelligence to compete.
02 Objectives
What we set out to do
Atlas was designed around five clear objectives, each addressing one of the problems above.
- 01One unified view: aggregate 20 real-world data sources into a single platform, one place to see any molecule from every angle.
- 02Automated scoring: score every molecule across 10 strategic dimensions on a 0–100 scale, classified into five funnel bands, without analyst effort.
- 03Faster decisions: cut strategic review cycles from weeks to hours by surfacing intelligence in structured, ready-to-use form.
- 04Accessible to mid-market: deliver enterprise-grade pharmaceutical intelligence to teams without enterprise-scale IT budgets.
- 05AI-native by design: synthesise signals, generate executive summaries, detect emerging risks, and answer questions in natural language.
03 Who uses it
Six roles, one source of truth
Atlas serves teams across the pharmaceutical value chain, from C-suite executives who need board-ready intelligence to scientific affairs teams who need molecule-level literature and safety surveillance. Each role gets exactly the view it needs.
Head of Business Development
Complete 360° per molecule, trials, approvals, safety, competition, before approaching licensing or partnership conversations.
Strategy Analyst
Scorecard analysis, watchlist monitoring, and deep dives into trial landscape and safety signals to build portfolio recommendations.
Regulatory Affairs Lead
Multi-market approval status (FDA / EMA / CDSCO), patent and exclusivity windows, and drug-label access.
Medical / Scientific Affairs
Literature search across PubMed, PMC and Europe PMC, pharmacovigilance signals, and safety surveillance per molecule.
Portfolio Manager
Opportunity pipeline tracking, watchlist management, and configurable alerts for score changes, trial transitions, and patent expiry.
Company types we serve
Mid-to-large pharma
Strategic portfolio reviews, in-licensing, pipeline prioritisation.
CDMOs
Identifying molecule opportunities, winning new business, informing pricing strategy.
Biotechnology companies
Early-stage pipeline intelligence, competitive positioning, BD outreach.
CROs
Scientific intelligence support, regulatory strategy, trial landscape analysis.
Pharma BD & M&A teams
Deal sourcing, molecule due diligence, market-sizing validation.
04 Capabilities
14 capabilities, four domains
Decision intelligence for leadership and portfolio teams, clinical and regulatory intelligence for approvals and trials, safety and scientific intelligence for surveillance and literature, and AI and discovery for knowledge graphs, natural language, and news signals.
Decision Intelligence
Molecule 360° View
A complete intelligence card per molecule: trials, approvals, safety, literature, drug labels, patents, news, and knowledge-graph relationships, all in one place.
Scorecard Engine
Ten-dimension scoring (0–100) across market attractiveness, patent window, regulatory maturity, demand, competition, feasibility, risk, fit, customer pull, and news momentum. Five funnel bands from High Priority to Excluded.
Board Cockpit
A C-suite dashboard with one-click AI-generated executive summaries, top opportunity rankings, and portfolio risk alerts.
Portfolio Management
Structured opportunity cards per molecule, multi-molecule tracking, and strategic-rationale capture, built for BD and investment decisions.
Watchlist & Alerts
Configurable watchlists with threshold-based alerts for score changes, new safety signals, patent-expiry windows, and trial-status transitions.
Clinical & Regulatory Intelligence
Trial Landscape
Unified trial intelligence across four international registries (ClinicalTrials.gov, WHO ICTRP, EU CTIS, CTRI India): phase, status, sponsor, location, and condition in one view.
Regulatory Intelligence
Multi-market approval tracking across FDA, EMA, and CDSCO India, with patent windows, exclusivity tracking, and regulatory-pathway suggestions.
Drug Labeling
Structured product labels linked directly to molecules and products, with RX / OTC / Biologic classifications and code mapping.
Safety & Scientific Intelligence
Safety Intelligence
FDA FAERS adverse-event signals and PvPI India pharmacovigilance data, with PRR and ROR analysis to quantify signal strength per molecule.
Literature Intelligence
Cross-database literature search across PubMed, PMC, and Europe PMC, with molecule-publication linking and cross-source deduplication.
AI & Discovery
Knowledge Graph
Eight relationship types connecting molecules to trials, approvals, indications, publications, safety signals, synonyms, and ontology concepts for complex cross-entity queries.
Pharma News Intelligence
28 pharma and biotech news feeds monitored continuously, with automatic molecule tagging and 12-category risk-signal detection.
AI Agent Interface
Natural-language queries across all platform data: ask about any molecule, trial, approval, safety signal, or market trend in plain English.
Ontology Browser
Unified MeSH, RxNorm, and ICD-10-CM concept navigation across the semantic knowledge graph that underpins all molecule linking.
05 The foundation
Enterprise-grade, always current
Atlas is built for the realities of pharmaceutical work: live data, private AI, enterprise security, and nothing to install.
Always-current intelligence
20 live sources are ingested, normalised and enriched continuously through an automated pipeline, so what you see is live data, not a stale monthly report.
AI-native
Private AI models generate executive summaries, extract entities, and answer natural-language questions, with semantic search across 17,000+ compounds.
Enterprise-grade and secure
Runs on enterprise cloud infrastructure with five-tier role-based access, so each person sees only what they need, from board summaries to regulatory deep dives.
Nothing to install
A cloud web application that runs in any modern browser, with no software to deploy or maintain.
Stop assembling intelligence by hand.
Atlas pulls from 20 live sources and scores your entire pipeline, so your team spends its time on decisions, not data collection.